Evotec erforscht Wirkstoffe für neue Arzneien unter anderem gegen Alzheimer, Krebs oder Diabetes. Partner sind dabei Pharma- und Biotechnologieunternehmen. Sitz ist in Hamburg.
COMPANY
INVESTOR TERMSHEET
EVT

Evotec
#BGFL Mood: Neutral · #BGFL-Indicator: Hold · Review date: -
LEI: 529900F9KI6OYITO9B12
SECTOR: Gesundheit SUB-SECTOR: Biotechnologie
NAME
Evotec
WKN
566480
ISIN
DE0005664809
TICKER
EVT
INDEX
MDAX
EXCHANGE
Xetra
Made with ❤ von BGFL

Evotec: In order to gain a valid impression of the companies' operating performance, boersengefluester.de (BGFL) has summarised the key figures in table form. Where individual figures are still estimates, they are taken from BGFL.

The most important financial data at a glance
  2015 2016 2017 2018 2019 2020 2021 2022 2023 2024e
Sales1 127,68 164,51 257,63 375,41 446,44 500,92 618,03 751,45 781,43 895,00
EBITDA1,2 8,69 36,23 57,22 95,46 123,14 51,77 101,65 102,51 66,35 140,00
EBITDA-Margin3 6,81 22,02 22,21 25,43 27,58 10,34 16,45 13,64 8,49 15,64
EBIT1,4 11,64 31,34 37,50 77,46 62,59 48,52 41,00 20,85 -47,51 30,00
EBIT-Margin5 9,12 19,05 14,56 20,63 14,02 9,69 6,63 2,78 -6,08 3,35
Net Profit (Loss)1 16,52 26,84 24,00 84,06 37,23 6,25 215,51 -175,66 -83,91 17,00
Net-Margin6 12,94 16,32 9,32 22,39 8,34 1,25 34,87 -23,38 -10,74 1,90
Cashflow1,7 15,65 67,36 10,83 156,24 42,22 44,72 122,24 203,11 36,44 0,00
Earnings per share8 0,12 0,20 0,16 0,46 0,25 0,04 1,30 -0,99 -0,47 0,11
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: BDO

Broadly speaking, there are two different methods of analysis on the stock market: Chart analysis, which focuses exclusively on price trends, and fundamental analysis, which looks at the development of companies' key operating figures. BGFL has more to offer on the fundamentals of German equities than almost anyone else.

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL